Sunitinib malate in solitary fibrous tumor (SFT)

S. Stacchiotti; T. Negri; M. Libertini; E. Palassini; A. Marrari; B. De Troia; A. Gronchi; A. P. Dei Tos; C. Morosi; A. Messina; S. Pilotti; P. G. Casali

doi:10.1093/annonc/mds143

Sunitinib malate in solitary fibrous tumor (SFT)

S. Stacchiotti, T. Negri, M. Libertini, E. Palassini, A. Marrari, B. De Troia, A. Gronchi, A. P. Dei Tos, C. Morosi, A. Messina, S. Pilotti, P. G. Casali

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

Background: To report on sunitinib activity in a retrospective series of 35 solitary fibrous tumor (SFT) treated at a single institution. Patients and methods: From April 2008, 35 patients with progressive advanced SFT (male/female: 20/15; mean age: 58 years; meningeal/extrameningeal: 6/29; locally advanced/metastatic: 15/20; prior chemotherapy: 25) were treated, on an individual use basis, with continuous-dosing sunitinib 37.5 mg/day. Platelet-derived growth factor receptor beta (PDGFRB) and vascular endothelial growth factor receptor 2 (VEGFR2) status were assessed by immunohistochemistry and, in a subgroup of patients, by real time PCR. Results: Thirty-one patients were assessable for response by RECIST (one early death; three early interruptions). Best responses were 2 partial response (PR), 16 stable disease, 13 progressive disease. A

Original language	English
Article number	mds143
Pages (from-to)	3171-3179
Number of pages	9
Journal	Annals of Oncology
Volume	23
Issue number	12
DOIs	https://doi.org/10.1093/annonc/mds143
Publication status	Published - Dec 2012

Keywords

Chemotherapy
Hemangioperycitoma
Sarcoma
Solitary fibrous tumor
Sunitinib
Tyrosine kinase inhibitors

ASJC Scopus subject areas

Oncology
Hematology

Access to Document

10.1093/annonc/mds143

Cite this

@article{5c63c49d54ad4c2f9d2803e516287605,

title = "Sunitinib malate in solitary fibrous tumor (SFT)",

abstract = "Background: To report on sunitinib activity in a retrospective series of 35 solitary fibrous tumor (SFT) treated at a single institution. Patients and methods: From April 2008, 35 patients with progressive advanced SFT (male/female: 20/15; mean age: 58 years; meningeal/extrameningeal: 6/29; locally advanced/metastatic: 15/20; prior chemotherapy: 25) were treated, on an individual use basis, with continuous-dosing sunitinib 37.5 mg/day. Platelet-derived growth factor receptor beta (PDGFRB) and vascular endothelial growth factor receptor 2 (VEGFR2) status were assessed by immunohistochemistry and, in a subgroup of patients, by real time PCR. Results: Thirty-one patients were assessable for response by RECIST (one early death; three early interruptions). Best responses were 2 partial response (PR), 16 stable disease, 13 progressive disease. A ",

keywords = "Chemotherapy, Hemangioperycitoma, Sarcoma, Solitary fibrous tumor, Sunitinib, Tyrosine kinase inhibitors",

author = "S. Stacchiotti and T. Negri and M. Libertini and E. Palassini and A. Marrari and {De Troia}, B. and A. Gronchi and {Dei Tos}, {A. P.} and C. Morosi and A. Messina and S. Pilotti and Casali, {P. G.}",

year = "2012",

month = dec,

doi = "10.1093/annonc/mds143",

language = "English",

volume = "23",

pages = "3171--3179",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "12",

}

TY - JOUR

T1 - Sunitinib malate in solitary fibrous tumor (SFT)

AU - Stacchiotti, S.

AU - Negri, T.

AU - Libertini, M.

AU - Palassini, E.

AU - Marrari, A.

AU - De Troia, B.

AU - Gronchi, A.

AU - Dei Tos, A. P.

AU - Morosi, C.

AU - Messina, A.

AU - Pilotti, S.

AU - Casali, P. G.

PY - 2012/12

Y1 - 2012/12

N2 - Background: To report on sunitinib activity in a retrospective series of 35 solitary fibrous tumor (SFT) treated at a single institution. Patients and methods: From April 2008, 35 patients with progressive advanced SFT (male/female: 20/15; mean age: 58 years; meningeal/extrameningeal: 6/29; locally advanced/metastatic: 15/20; prior chemotherapy: 25) were treated, on an individual use basis, with continuous-dosing sunitinib 37.5 mg/day. Platelet-derived growth factor receptor beta (PDGFRB) and vascular endothelial growth factor receptor 2 (VEGFR2) status were assessed by immunohistochemistry and, in a subgroup of patients, by real time PCR. Results: Thirty-one patients were assessable for response by RECIST (one early death; three early interruptions). Best responses were 2 partial response (PR), 16 stable disease, 13 progressive disease. A

AB - Background: To report on sunitinib activity in a retrospective series of 35 solitary fibrous tumor (SFT) treated at a single institution. Patients and methods: From April 2008, 35 patients with progressive advanced SFT (male/female: 20/15; mean age: 58 years; meningeal/extrameningeal: 6/29; locally advanced/metastatic: 15/20; prior chemotherapy: 25) were treated, on an individual use basis, with continuous-dosing sunitinib 37.5 mg/day. Platelet-derived growth factor receptor beta (PDGFRB) and vascular endothelial growth factor receptor 2 (VEGFR2) status were assessed by immunohistochemistry and, in a subgroup of patients, by real time PCR. Results: Thirty-one patients were assessable for response by RECIST (one early death; three early interruptions). Best responses were 2 partial response (PR), 16 stable disease, 13 progressive disease. A

KW - Chemotherapy

KW - Hemangioperycitoma

KW - Sarcoma

KW - Solitary fibrous tumor

KW - Sunitinib

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84869792128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869792128&partnerID=8YFLogxK

U2 - 10.1093/annonc/mds143

DO - 10.1093/annonc/mds143

M3 - Article

C2 - 22711763

AN - SCOPUS:84869792128

VL - 23

SP - 3171

EP - 3179

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 12

M1 - mds143

ER -

Sunitinib malate in solitary fibrous tumor (SFT)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this